IPR v. Ex Parte Reexam Strategy Considerations

Looking forward to presenting at the AIPLA IP Practice in Japan Mid-Winter Program in Houston, TX next week!

I will be discussing the strategic considerations for Inter Partes Review (IPR) versus Ex Parte Reexamination, including:

• The procedural differences between IPR and Ex Parte Reexamination and associated statistics
• The circumstances when one may be preferable over the other
• The effects of timing and estoppel in parallel litigations

My colleague, Jason Murata, another partner in Axinn’s Intellectual Property group, will be covering, “Recent Developments in the Generic Pharma Industry in the U.S.”